فاس نيوز ميديا جريدة الكترونية جهوية تعنى بشؤون و أخبار جهة فاس مكناس – متجددة على مدار الساعة
Rabat – MAP
In a move aimed at reassuring the public, the Moroccan Agency for Medicines and Health Products (AMMPS) denied, this Tuesday, rumors circulating about a severe shortage of more than 600 essential medicines in Morocco. The Agency confirmed that no major supply disruption has been observed to date.
This clarification came in an official communiqué from the AMMPS, in its capacity as the national authority for regulating and controlling the pharmaceutical sector. The Agency affirmed that available national data confirm that there has been no significant impact on the functioning of the healthcare system thus far.
Agency Acknowledges “Temporary” Shortages for Some Medicines and Explains Causes
However, the Agency acknowledged that “occasional stockouts of certain pharmaceutical specialties may occur,” a phenomenon observed internationally, “mainly linked to tensions affecting supply chains, difficulties in accessing raw materials, or fluctuations in global markets.”
The communiqué added that although these constraints are beyond the control of a single country, the Kingdom of Morocco is proactively implementing all necessary measures to mitigate their impact and ensure the continuity of treatment for patients.
A Permanent Vigilance Mechanism to Monitor the Market
The Agency explained that it continuously coordinates its efforts with the Ministry of Health and Social Protection and all other stakeholders. Within this framework, the “Market Watch and Monitoring Service” operates on a permanent mission to monitor and analyze the national drug supply, proactively detect any supply tensions, and deploy rapid and targeted corrective measures when necessary to preserve access to essential medicines.
The Agency highlighted that this mechanism has already proven its effectiveness by proactively anticipating and managing at-risk situations before they could impact patients.
National Drug Sovereignty Strategy at the Heart of the Response
The Agency also revealed that, as part of the national drug sovereignty strategy, it is implementing a structured policy based on three main priorities:
- Strengthening Local Production: By increasing the share of medicines manufactured in Morocco, with the aim of reducing dependence on imports and stabilizing the market.
- Promoting Competition and the Development of Generics: By limiting monopoly situations and ensuring accessible therapeutic alternatives.
- Securing the Supply of Vital Medicines: Through proactive planning, diversification of sources, and the establishment of strategic stockpiles.
The communiqué concluded that by betting on permanent vigilance, the diversification of supplies, and the strengthening of national production, Morocco aims to transform these global challenges into levers of resilience. This affirms that in the face of market uncertainties, the health of citizens remains an untouchable priority, protected by a firmly anchored drug sovereignty strategy.
